Cost-effectiveness analysis of bortezomib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (VR-CAP) in patients with previously untreated mantle cell lymphoma

被引:0
作者
Marjolijn van Keep
Kerry Gairy
Divyagiri Seshagiri
Pushpike Thilakarathne
Dawn Lee
机构
[1] BresMed,
[2] Janssen-Cilag,undefined
[3] Janssen-Cilag,undefined
[4] Janssen-Cilag,undefined
[5] BresMed,undefined
来源
BMC Cancer | / 16卷
关键词
Bortezomib; Mantle cell lymphoma; Cost effectiveness; VR-CAP; R-CHOP;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 103 条
[1]  
Smith A(2015)Lymphoma incidence, survival and prevalence 2004-2014: sub-type analyses from the Uk’s Haematological Malignancy Research Network Br J Cancer 112 1575-84
[2]  
Crouch S(2012)British Committee for Standards in Haematology. Guidelines for the investigation and management of mantle cell lymphoma Br J Haematol 159 405-26
[3]  
Lax S(2012)Mantle cell lymphoma Crit Rev Oncol Hematol 82 78-101
[4]  
Li J(2012)Mantle cell lymphoma: a clinically heterogeneous disease in need of tailored approaches Cancer Control 19 227-35
[5]  
Painter D(2014)Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 25 iii83-92
[6]  
Howell D(2015)Mantle cell lymphoma: evolving management strategies Blood 125 48-55
[7]  
McKay P(2013)ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma Ann Oncol 24 857-77
[8]  
Leach M(2013)Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 11th annual conference of the European Mantle Cell Lymphoma Network Leuk Lymphoma 54 699-707
[9]  
Jackson R(2008)A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma Blood 111 558-65
[10]  
Cook G(2012)Treatment of older patients with mantle-cell lymphoma N Engl J Med 367 520-31